ETORICOXIB-LOADED SOLID LIPID NANOPARTICLE DOSAGE FORM: FORMULATION, OPTIMIZATION, CHARACTERIZATION, STABILITY STUDYAND IN-VITRO IN-VIVO EVALUATION

Objective: The aim of present research work is to increase the bioavailability of poorly water soluble drug etoricoxib by developing solid lipid nanoparticle (SLN). Due to their unique size dependent properties, lipid nanoparticles offer the possibility to develop new therapeutics and enhance the bioavailability.Methods: An aqueous-based etoricoxib loaded solid lipid nanoparticles were prepared by hot and high speed homogenization technique, using different ratio of stearic acid and tripalmitin as lipid and different amount of pluronic F-68 as emulsifier. Optimization was done by surface response methodology (SRM) technique. The formulations are charecterised by drug content, drug entrapment efficiency, particle size and zea potential determination, SEM etc and evaluated by pharmacokinetic, pharmacodynamic and stability study.Results: Particle size distribution, entrapment efficiency and drug release were found 499.20 nm, 72% and 98.36% simultaneously, for selected optimized formulations. Zeta potential and span of optimized formulation found to be within the range of+34.2±0.9 and 0.29. in-vivo studies shows that pain reaction time (PRT) has increased from 6.2±0.42 to 8.45±0.19 second. Pharmacokinetic study shows an increasing remarkable result for Cmax which one is increased from 6274.290 μg ml−1 h to 8558.134 μg ml−1 h when compared with the standard formulation and for AUC it has been observed from 94202.963 mg. h. l-1 to 124310.201 mg. h. l-1Conclusion: Development of SLN formulations could be a better approach to increase the bioavailability of poorly water soluble drug like etoricoxib.Â

Evaluation of the role of erythropoietin and methotrexate in multiple sclerosis

Background : Erythropoietin, originally recognized for its role in erythropoiesis, has been shown to improve neurological outcome after stroke. Low-dose methotrexate is effective against certain inflammatory diseases, such as severe psoriasis and rheumatoid arthritis as well as Crohn's disease. Immunosuppressive effect of methotrexate also reduces the proportion of patients with chronic progressive multiple sclerosis with modest clinical benefits. Combination of erythropoietin and methotrexate can target neuroinflammation along with immunosupression. Objective : To evaluate the role of erythropoietin and methotrexate in experimental autoimmune encephalomyelitis, a commonly used animal model of several degenerative human diseases like multiple sclerosis. Materials and Methods : In the present study, C57BL/J6 mice were immunized with 200 mg of myelin basic protein (MBP) emulsified in complete Freund's adjuvant (CFA) supplemented with 1 mg/ml of killed mycobacterium tuberculosis (MBP: CFA in 1:1 ratio). These animals were given a combination of methotrexate and erythropoietin. Neurological function tests were scored daily by grading of clinical signs. Cerebral histopathology was performed to detect inflammatory infiltrates and demyelination. Results : Treatment with erythropoietin and methotrexate significantly improved the neurological function recovery, reduced inflammatory infiltrates, and demyelination as compared to controls possibly by stimulating oligodendrogenesis and down-regulating proinflammatory infiltrates. Conclusion : The findings suggest an adjunctive use of methotrexate in demyelinating disease